Research Analysts Set Expectations for VYGR FY2025 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Voyager Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($2.03) per share for the year, up from their prior estimate of ($2.20). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the business earned $1.25 EPS.

Other equities analysts have also recently issued research reports about the company. StockNews.com cut Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, March 13th. Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a "buy" rating and a $12.00 target price for the company. Finally, Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics presently has an average rating of "Buy" and a consensus price target of $14.86.

Remove Ads

Voyager Therapeutics Trading Down 0.3 %

Shares of NASDAQ VYGR traded down $0.01 during mid-day trading on Friday, hitting $3.88. The company had a trading volume of 374,048 shares, compared to its average volume of 477,763. The company has a market capitalization of $211.95 million, a PE ratio of 5.46 and a beta of 0.99. The firm has a 50-day simple moving average of $4.79 and a two-hundred day simple moving average of $5.80. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vestal Point Capital LP raised its position in shares of Voyager Therapeutics by 151.0% in the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock valued at $6,974,000 after buying an additional 740,000 shares in the last quarter. Virtus Investment Advisers Inc. raised its position in shares of Voyager Therapeutics by 59.0% in the fourth quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company's stock valued at $114,000 after buying an additional 7,457 shares in the last quarter. Tema Etfs LLC acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $85,000. Man Group plc acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $234,000. Finally, Farallon Capital Management LLC increased its stake in Voyager Therapeutics by 12.2% in the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock valued at $14,576,000 after acquiring an additional 278,700 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 10,778 shares of company stock worth $58,548 over the last three months. Insiders own 4.53% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.